Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first glimpse into how much Medicare can leverage its newfound power to negotiate down drug prices.
2024年将是医疗保健行业的关键时刻，尤其是在药品定价谈判中。来年将让人们第一次看到医疗保险可以在多大程度上利用其新获得的力量来谈判降低药品价格。
President Joe Biden's Inflation Reduction Act, passed last year, granted Medicare authority to directly engage in price discussions with drug manufacturers, heralding a substantial shift in the program's longstanding history.
去年通过的乔·拜登总统的《通货膨胀降低法》授权医疗保险直接与药品制造商进行价格讨论，这预示着该计划的长期历史将发生重大转变。
The negotiation process initiated by Medicare, set to begin on February 1, will encompass ten prescription drugs from various pharmaceutical giants, including Merck & Co Inc (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), and Bristol Myers Squibb & Co (NYSE:BMY), among others. These discussions aim to make costly treatments more accessible for older Americans, with the agreed-upon prices taking effect in 2026.
由Medicare启动的谈判过程定于2月1日开始，将涵盖来自不同制药巨头的十种处方药，包括默沙东公司（纽约证券交易所代码：MRK）、强生（纽约证券交易所代码：JNJ）和百时美施贵宝公司（纽约证券交易所代码：BMY）等。这些讨论旨在使美国老年人更容易获得昂贵的治疗，商定的价格将于2026年生效。
The eventual price adjustments will dictate the potential revenue loss for drug manufacturing companies in the coming years, CNBC writes.
CNBC写道，最终的价格调整将决定药品制造公司未来几年的潜在收入损失。
These figures will also offer insights to other pharmaceutical companies regarding the potential impact on their sales should their medications be chosen for future negotiation rounds.
这些数字还将为其他制药公司提供见解，让他们了解如果未来几轮谈判选择他们的药物，会对他们的销售产生什么潜在影响。
The pharmaceutical industry perceives this negotiation process as threatening revenue growth and drug innovation.
制药行业认为这一谈判过程威胁着收入增长和药物创新。
Simultaneously, these negotiations hold substantial significance for patients, offering insight into the potential savings they might experience, crucial amid the escalating challenges many face in affording essential medications.
同时，这些谈判对患者具有重大意义，可以深入了解他们可能节省的费用，这对于许多人在购买基本药物方面面临的挑战不断升级的情况下至关重要。
The upcoming decisions in ongoing lawsuits, primarily led by major pharmaceutical entities and industry groups against the Biden administration, will shape the legal landscape.
正在进行的诉讼中即将作出的决定将塑造法律格局，这些诉讼主要由主要制药实体和行业团体牵头，针对拜登政府。
These cases, disputing the constitutionality of the negotiations, will likely make significant progress in appeals courts throughout 2024, potentially accelerating the process toward a Supreme Court resolution by 2025.
这些案件对谈判的合宪性存在争议，很可能会在整个2024年在上诉法院取得重大进展，有可能加快最高法院到2025年达成决议的进程。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明： 该内容部分是在人工智能工具的帮助下制作的，并由Benzinga编辑审阅和发布。
Image by Steve Buissinne from Pixabay
图片由 Pixabay 的 Steve Buissinne 拍摄